GammaDelta Therapeutics Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
GammaDelta Therapeutics Ltd. - overview
Established
2016
Location
London, -, UK
Primary Industry
Biotechnology
About
GammaDelta Therapeutics Ltd. specializes in innovative cell therapy solutions to treat cancer and other diseases by harnessing the power of gamma delta T cells, contributing to advancements in immunotherapy. Founded in 2016, GammaDelta Therapeutics Ltd. is based in London, UK, and focuses on developing novel therapies utilizing gamma delta T cells.
The company was acquired by Takeda Pharmaceutical Company Limited in October 2021, a strategic move aimed at enhancing their therapeutic offerings. The CEO is Paolo Paoletti, and the founder is Adrian Hayday, who has a notable history in immunology and cell therapy. In total, the company has successfully executed 3 deals, with its latest funding round accumulating USD 100. 00 mn from investors including Abingworth and Takeda Ventures, bringing the total amount raised to USD 100.
00 mn. GammaDelta Therapeutics offers a range of cell therapy products focused on utilizing gamma delta T cells for cancer treatment. Their innovative therapies are at the forefront of immunotherapy, targeting various malignancies and advancing research in the oncology field. The company emphasizes developing unique therapeutic approaches that leverage the body's immune system to combat tumor cells effectively.
In the most recent fiscal year of 2023, GammaDelta Therapeutics achieved a revenue of USD 43. 12 mn, with an EBITDA of USD 7. 18 mn. The company's revenue generation model primarily includes direct sales of its therapies and partnerships with healthcare providers to enhance patient access to these innovative treatments.
GammaDelta Therapeutics is committed to expanding its product pipeline with upcoming therapies aimed at treating various cancers, with specific launch dates yet to be announced. The company plans to broaden its market presence into North America and Europe, leveraging its recent funding of USD 100. 00 mn to support these initiatives. The acquisition by Takeda is expected to enhance their capabilities and expedite the development of their therapeutic offerings.
Current Investors
Abingworth, King's College London Endowment, Cancer Research Technology Ltd.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.gammadeltatx.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
GammaDelta Therapeutics Ltd. - timeline of key events
GammaDelta Therapeutics Ltd. - financials
| Fiscal Year Ended | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | Mar 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue (USD) | 10,633,156 | 12,292,345 | 17,654,215 | - | - | - |
| % Revenue Growth (YoY) | - | 15.6% | 43.6% | - | - | - |
| EBITDA (USD) | (3,823,353) | (8,372,652) | (4,973,194) | - | - | - |
| Operating Income (USD) | (4,405,363) | (9,467,369) | (6,169,833) | - | - | - |
| Operating Margin | (41.4%) | (77.0%) | (34.9%) | - | - | - |
| % EBITDA Margin | (36.0%) | (68.1%) | (28.2%) | - | - | - |
| NET Income (USD) | (4,682,256) | (9,616,231) | (6,498,365) | - | - | - |
| % Net Margin | (44.0%) | (78.2%) | (36.8%) | - | - | - |
GammaDelta Therapeutics Ltd. - employee data
GammaDelta Therapeutics Ltd. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Co-founder and Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.